Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Pediatric Chronic Kidney Disease
NCT06430684Phase 1Recruiting
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Start
- Aug 2024
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin in chronic kidney disease (CKD) (2 arms), sponsored by Ann & Robert H Lurie Children's Hospital of Chicago. Primary endpoint: Percentage of participants who complete all study procedures at 4 years. Started Aug 2024; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06430684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06430684.